Skip to main content

Table 2 Diagnostic performances of criteria in the ACR/EULAR 2016 score

From: Unstimulated whole saliva flow for diagnosis of primary Sjögren’s syndrome: time to revisit the threshold?

 Schirmer ≤ 5 mm/5 minUWS ≤ 0.1 mL/minAnti-SSA antibodiesFocus score ≥ 1/4 mm2
Whole population (n = 185)
 Se (%)89.2 [81.1–94.7]43.0 [32.8–53.7]37.6 [27.8–48.3]91.4 [83.8–96.2]
 Sp (%)29.3 [20.3–39.8]73.9 [63.7–82.5]100 [96.1–100]91.3 [83.6–96.2]
 PPV (%)56.1 [47.7–64.2]62.5 [49.5–74.3]100 [90.0–100]91.4 [83.8–96.2]
 NPV (%)73.0 [55.9–86.2]56.2 [46.9–65.2]61.3 [53.0–69.2]91.3 [83.6–96.2]
Men (n = 38)
 Se (%)100 [79.4–100]56.3 [29.9–80.2]25.0 [7.3–52.4]87.5 [61.7–98.4]
 Sp (%)22.7 [7.8–45.4]90.9 [70.8–98.9]100 [84.6–100]95.5 [77.2–99.9]
 PPV (%)48.5 [30.8–66.5]81.8 [48.2–97.7]100 [39.8–100]93.3 [68.1–99.8]
 NPV (%)100 [47.8–100]74.1 [53.7–88.9]64.7 [46.5–80.3]91.3 [72.0–98.9]
Women < 50 (n = 42)
 Se (%)68.8 [41.3–89.0]50.0 [54.7–75.3]56.3 [29.9–80.2]93.8 [69.8–99.8]
 Sp (%)46.2 [26.6–66.6]80.8 [60.6–93.4]100 [86.8–100]92.3 [74.9–99.1]
 PPV (%)44.0 [24.4–65.1]61.5 [31.6–86.1]100 [66.4–100]88.2 [63.6–98.5]
 NPV (%)70.6 [44.0–89.7]72.4 [52.8–87.3]78.8 [61.1–91.0]96.0 [79.6–99.9]
Women ≥ 50 (n = 105)
 Se (%)91.8 [81.9–97.3]37.7 [25.6–51.0]36.1 [24.2–49.4]91.8 [81.9–97.3]
 Sp (%)22.7 [11.5–37.8]61.4 [45.5–75.6]100 [92.0–100]88.6 [75.4–96.2]
 PPV (%)62.2 [51.4–72.2]57.5 [40.9–73.0]100 [84.6–100]91.8 [81.9–97.3]
 NPV (%)66.7 [38.4–88.2]41.5 [29.4–54.4]53.0 [41.7–64.1]88.6 [75.4–96.2]
  1. UWS unstimulated whole saliva flow rate, Se sensitivity, Sp specificity, PPV positive predictive value, NPV negative predictive value
\